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Oxidative stressAbstract Genetic, environmental factors, dysregulation of immune system, intestinal microbes and
oxidative stress are the most important factors that play the role in the pathogenesis of inﬂamma-
tory bowel disease (IBD). Current treatments do not always result in complete remission and usu-
ally accompanied with several adverse effects. Recent studies showed that nuclear factor-kappa B
(NF-jB), tumor necrosis factor-a (TNF-a) and oxidative stress play the pivotal role in the induction
of inﬂammation. Butyrate, L-Carnitine, and probiotics have the potential to control inﬂammation
by reduction of main inﬂammatory cytokines, including NF-jB and TNF-a. They also stimulate
antioxidant enzymes and inhibit IjB kinase (IKK). Regarding the beneﬁcial effects of these three
compounds in inﬂammation via several mechanisms, we hypothesize that the mixture of these com-
pounds would be synergistically effective in reduction of inﬂammation and alleviation of IBD. Fur-
ther experimental investigations are needed, to evaluate the hypothesis.
ª 2013 Tehran University of Medical Sciences. Published by Elsevier Ltd.Open access under CC BY-NC-ND license.Introduction
Inﬂammatory bowel disease (IBD), representing as ulcerative
colitis (UC) or Crohn’s disease (CD), with an increasing
incidence, can be debilitating in affected patients. It associates
with colonic mucosal inﬂammation that causes bloody
diarrhea and abdominal pain. Although, activation of
inﬂammatory process and oxidative stress are believed to be21 66959104.
.ir, mohammad.abdollahi@utoron
niversity of Medical Sciences. Pub
h/
/j.jmhi.2013.02.003the main causes to the disease, but the exact pathophysiology
of IBD is under debate yet [1–4]. The most of currently used
medicines can only reduce the severity of IBD symptoms and
cannot cure the disease or do not result in complete remission
[5]. Conventional treatments are accompanied with several
adverse effects resulting in less tolerability and compliance in
patients [2,6,7]. Therefore, in the recent years, many investiga-
tions have been done to develop new natural, non-syntheticto.ca (M. Abdollahi).
lished by Elsevier Ltd. Open access under CC BY-NC-ND license.
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efﬁcacies [4,8,9]. Previous studies have shown the efﬁcacy of
butyrate, L-Carnitine, and probiotics in IBD when used alone
or in combination with conventional therapies [10–13]. These
compounds have the potential to control inﬂammation by
reduction of main inﬂammatory cytokines, the nuclear fac-
tor-kappa B (NF-jB) and tumor necrosis factor-a (TNF-a),
which play the pivotal role in induction and progress of IBD
[14–17]. The protective effect of butyrate, L-Carnitine, and pro-
biotics against oxidative stress, is well documented based upon
the results from previous studies.
Butyrate is produced naturally by bacterial fermentation in
colonocytes. It affects IkB kinase (IKK) by suppressing phos-
phorylation of IkB-a or IkB-b. This results in reducing the
stimulation of NF-jB pathway and thus decreases the level
of reactive oxygen species (ROS) [2,16,18–23]. In addition,
butyrate prevents elevation of TNF-a which occurs during
the process of inﬂammation. Then, silencer of death domain
(SODD) dissociates from adaptor protein so called TNF
receptor type 1-associated death domain protein (TRADD),
which ﬁnally activates the ribosome inactivating protein
(RIP) and TNF receptor associated factor 2 (TRAF2). These
activated proteins stimulate IKK and NF-jB [14,24].
On the other hand, probiotics have preventive effects on the
induction of NF-jB, either directly or indirectly. They can de-
lay degradation of IkB-a, so they inhibit the activation of NF-
jB, expression of TNF-a and other pro-inﬂammatory cyto-
kines. In addition, by producing anti-oxidant enzymes such
as superoxide dismutase (SOD) and catalase (CAT), probiotics
act against ROS, which induces IKK [18,25].
The third compound L-Carnitine (b-hydroxy-c trimethyla-
mino butyrate) has anti-oxidant activity as mainly reducesFigure 1 The effects of butyrate, L-Carnitine, and probiotics on IKK
iNOS: inducible Nitric Oxide Synthase; NO: Nitric Oxide; NF-jB: Nu
Reactive Oxygen Species; TNF: Tumor Necrosis Factor; TNF-R: Tum
Receptor Type 1-Associated Death Domain Protein; TRAF2: Tumor N
Death Domain.myeloperoxidase (MPO) and malondialdehyde (MDA), two
active elements of oxidative stress. L-Carnitine up-regulates
SOD and prevents reduction of glutathione (GSH). It also
inhibits accumulation of lipid peroxides. Therefore, it sup-
presses the formation and the activation of ROS, resulting in
inhibition of NF-jB pathway [15,20,23,26] (Fig. 1).
The hypothesis
It is revealed that suppression of NF-jB through inhibition of
IKK or via stimulating of antioxidant enzymes may suppress
oxidative stress. Based on the beneﬁcial effects of butyrate,
L-Carnitine and probiotics in inﬂammation, via mentioned
mechanisms, we hypothesize that combination of these com-
pounds would be synergistically effective in reduction of
inﬂammation.
Some studies support the present idea. For instance, probi-
otics cause an over expression in sodium-coupled mono car-
boxylate transporter 1 (SMCT1) gene, which is responsible
for butyrate’s absorptions. This gene is down regulated by
TNF-a. In addition, over expression of L-Carnitine’s trans-
porter (OCTN2) by Saccharomyces boulardii (a type of probi-
otics), and enhancement in the metabolism of butyrate (b
oxidation) by L-Carnitine have been demonstrated. Therefore,
by considering these interactions, the combination effect might
be a more advantageous in IBD treatment [22].
Evaluation of the hypothesis
To evaluate the efﬁcacy of combination treatment, ﬁrst, an
appropriate experimental model of IBD should be set up.. SOD: Superoxide Dismutase; CAT: Catalase; IKK: IjB Kinase;
clear Factor-kappa B; RIP: Ribosome Inactivating Protein; ROS:
or Necrosis Factor Receptor; TRADD: Tumor Necrosis Factor
ecrosis Factor Receptor Associated Factor 2; SODD: Silencer of
52 M. Moeinian et al.Among several models, dextran or trinitrobenzene sulfonic
acid (TNBS) induced colitis, are similar models to human
IBD with the most reproducibility. To set up the study, seven
groups, including, sham, negative, positive control, and four
treatment groups (each compound alone or in combination)
should be assigned. To prepare the mixture, containing these
three compounds, a proper formulation should be provided.
The effective doses of each compound and duration of treat-
ment should be adjusted based on literature and previous stud-
ies [27]. After the treatment period, macroscopic, microscopic
and biochemical bio markers of colon should be evaluated.
The main factors of bowel inﬂammation such as oxidative
stress markers and inﬂammatory cytokines, including TNF-a
and NF-jB, should be measured and compared among treat-
ment groups [14,16,21,23,28,29]. Given that dextran and
TNBS-induced colitis models are acute models, comparison
with dexamethasone as a positive control is proposed.
Discussion
Current treatments of IBD such as corticosteroids, immunosup-
pressive agents and 5-aminosalicylic acid (5-ASA) are not com-
pletely curative and satisfying. Recent studies have focused upon
the role of NF-jB, TNF-a and oxidative stress in the induction
of inﬂammation. Regarding the positive effects of butyrate, L-Car-
nitine and probiotics via regulation of main inﬂammatory cyto-
kines and anti-oxidant enzymes, we hypothesize that the
combination of these compounds would be synergistically effec-
tive in reducing inﬂammation and alleviation of IBD.
These compounds have protective effects against oxidative
stress through several mechanisms. Butyrate inhibits degrada-
tion of IkBa bound NF-jB (inhibitory protein) by suppression
of IKK. In colonic tropism, butyrate stimulates the prolifera-
tion of immature epithelial cells at the base of colonic crypts
and improves electrolyte absorption that leads to colonic re-
pair stimulation [30].
Several investigations have reported that probiotics such as
Lactobacillus casei, Biﬁdobacterium biﬁdum, and Saccharomy-
ces boulardii recover immune colitis and reduce pro-inﬂamma-
tory mediators inside the lamina propria of inﬂamed mucosa
[31,32]. They activate T-cells via Th1 or Th2 immune re-
sponses. Some studies have shown that probiotics decrease
the production of TNF-a, and the activation of NF-jB cas-
cade. They probably affect the innate immunity cells [33–37].
It has been clearly demonstrated that L-Carnitine can act as
an anti-inﬂammatory and anti-oxidant. It protects tissues from
ROS-induced damages. Several mechanisms of action of L-
Carnitine on T-cell activation remain hard to deﬁne L-Carni-
tine has a protective effect on the intestinal mucosa by prevent-
ing ROS production [37,38].
Considering the demonstrated beneﬁcial interactions between
probiotics, L-Carnitine and butyrate, when used in combination,
such as effects on the metabolism or expression of each other, it
is suggested that the mixture of these three compounds may be
effective in treatment of IBD by via the common pathways.
Conclusion
In conclusion, mixture of butyrate, L-Carnitine and probiotics
may have great anti-inﬂammatory and antioxidant propertiesvia down regulation of TNF-a, inhibition of NF-jB, or sup-
pression of ROS [19,20,23,25,27,28]. These beneﬁts would be
considered in therapy of IBD.
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First Question: What do we already know about
subject?
There are some information about pathogenesis of
IBD, therapeutic methods and alternative therapies.
Recent studies have shown positive effects of butyrate,
L-Carnitine and probiotics in IBD when used with con-
ventional therapies.
Second Question: What does your proposed theory add
to the current available knowledge and what beneﬁts does
it have?
Mixture of butyrate, L-Carnitine and probiotics can be
safely used in IBD patients as a novel and desirable com-
bination. By adding this combination to chemical therapy
of patients, then the doses of chemicals and thus chance of
adverse effects might be reduced.
Third question: Among numerous available studies, what
special further study is proposed for testing the idea?
Evaluation of inﬂammatory cytokines such as TNF-a,
NFjB, oxidative stress markers and, macroscopic and
biochemical factors by setting up an appropriate colitis
model is proposed.References
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